Trial Information
A Pilot Study to Investigate the Clinical Utility of the Peregrine Monte Carlo Dose Calculation System for Radiation Therapy Treatment Planning
The utility of PEREGRINE Monte Carlo calculations for radiation treatment planning in a
clinical setting will be assessed by comparing results with other fully three-dimensional
programs. ROB will investigate PEREGRINE for clinical use at NCI.
Inclusion Criteria
INCLUSION CRITERIA:
Patients with documented malignancy requiring standard radiotherapy OR patients with a
benign condition for whom radiotherapy is indicated.
EXCLUSION CRITERIA:
Documented connective tissue disease or Ataxia Telangiectasia.
Cognitively impaired patients who cannot give informed consent.
Other medical conditions deemed by the PI to make the patient ineligible.
Patients requiring emergent radiotherapy.
Patients who are not able to undergo a CT scan.
Type of Study:
Interventional
Study Design:
Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment
Authority:
United States: Federal Government
Study ID:
990116
NCT ID:
NCT00026936
Start Date:
May 1999
Completion Date:
January 2005
Related Keywords:
- Neoplasm
- External Beam Radiotherapy
- TCP
- DVH
- NTCP
- 3-D Programming
- Neoplasms
Name | Location |
| National Cancer Institute (NCI) |
Bethesda, Maryland 20892 |